New England Journal of Medicine· 2026Q1

Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

Amir Fathi, Alexander E. Perl, Geoffrey Fell, Brian A. Jonas et al.

1citations
Q1SCImago
2026year

Short summary

Azacitidine–venetoclax significantly improved event-free survival (14.5 months vs. 6.2 months) compared to induction chemotherapy in induction-eligible acute myeloid leukemia (AML) patients (n=172).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine